Journal article
GLP‐1 receptor agonists for Parkinson's disease
Abstract
BACKGROUND: Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain. Insulin signalling in the brain plays a key role in neuronal metabolism and repair and in synaptic …
Authors
Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
Journal
Cochrane Database of Systematic Reviews, Vol. 2020, No. 7,
Publisher
Wiley
DOI
10.1002/14651858.cd012990.pub2
ISSN
1361-6137